Ambys Medicines is developing cell therapies for liver diseases. Liver diseases impact millions of people, and rates of liver disease incidence and mortality are on the rise. Less than 10% of patients receive a liver transplant - hence the demand for alternative therapeutic strategies. Ambys focuses on understanding the biological processes that lead to liver injury with a vision of using these insights to develop therapies. Ambys is investigating allogeneic cell therapies that can deliver healthy hepatocytes to patients with acute or chronic liver diseases to restore function. Ambys’ first program, AMI-918, has been developed for acute liver disease and will enter human clinical trials in 2023.